X
Search Filters
Format Format
Subjects Subjects
Subjects Subjects
X
Sort by Item Count (A-Z)
Filter by Count
index medicus (16) 16
humans (15) 15
male (14) 14
female (13) 13
middle aged (13) 13
adult (11) 11
aged (11) 11
hematology (10) 10
lymphomas (10) 10
chemotherapy (7) 7
rituximab (7) 7
treatment outcome (7) 7
cancer (6) 6
abridged index medicus (5) 5
aged, 80 and over (5) 5
antineoplastic combined chemotherapy protocols - therapeutic use (5) 5
clinical trials (5) 5
drug administration schedule (5) 5
lymphoma (5) 5
medicine, general & internal (5) 5
therapy (5) 5
antibodies, monoclonal, murine-derived - administration & dosage (4) 4
antineoplastic combined chemotherapy protocols - adverse effects (4) 4
hematology, oncology and palliative medicine (4) 4
internal medicine (4) 4
leukemia (4) 4
neoplasm staging (4) 4
non-hodgkins-lymphoma (4) 4
survival analysis (4) 4
young adult (4) 4
[sdv.can]life sciences [q-bio]/cancer (3) 3
cyclophosphamide (3) 3
cyclophosphamide - administration & dosage (3) 3
cyclophosphamide - therapeutic use (3) 3
diagnosis (3) 3
doxorubicin - administration & dosage (3) 3
doxorubicin - therapeutic use (3) 3
life sciences (3) 3
lymphoma, large b-cell, diffuse - drug therapy (3) 3
lymphoma, large b-cell, diffuse - mortality (3) 3
monoclonal antibodies (3) 3
oncology (3) 3
prednisone (3) 3
prednisone - administration & dosage (3) 3
prednisone - therapeutic use (3) 3
vincristine (3) 3
vincristine - therapeutic use (3) 3
[ sdv ] life sciences [q-bio] (2) 2
[ sdv.can ] life sciences [q-bio]/cancer (2) 2
activities of daily living (2) 2
adolescent (2) 2
adults (2) 2
analysis (2) 2
angioimmunoblastic t-cell lymphoma (2) 2
antibodies, monoclonal, murine-derived - therapeutic use (2) 2
antineoplastic combined chemotherapy protocols (2) 2
antineoplastic combined chemotherapy protocols - administration & dosage (2) 2
b cells (2) 2
b-cell lymphoma (2) 2
chronic lymphocytic-leukemia (2) 2
cyclophosphamide - adverse effects (2) 2
cytarabine - administration & dosage (2) 2
dehydrogenases (2) 2
disease (2) 2
disease-free survival (2) 2
dose-response relationship, drug (2) 2
doxorubicin - adverse effects (2) 2
drug dosages (2) 2
drug therapy (2) 2
eculizumab (2) 2
epidemiology (2) 2
epstein-barr virus (2) 2
epstein-barr-virus (2) 2
expression (2) 2
features (2) 2
france (2) 2
free survival (2) 2
health aspects (2) 2
hemic and lymphatic diseases (2) 2
ibrutinib (2) 2
immunotherapy (2) 2
indolent (2) 2
low-grade (2) 2
lymphocytes b (2) 2
lymphoma, mantle-cell - drug therapy (2) 2
malignant-lymphoma (2) 2
mantle cell lymphoma (2) 2
medical prognosis (2) 2
medical research (2) 2
medicine, experimental (2) 2
multicenter (2) 2
myasthenia gravis (2) 2
plus rituximab (2) 2
prednisone - adverse effects (2) 2
proportional hazards models (2) 2
quality of life (2) 2
refractory materials (2) 2
response criteria (2) 2
retrospective studies (2) 2
safety and security measures (2) 2
more...
Language Language
Publication Date Publication Date
Click on a bar to filter by decade
Slide to change publication date range


Lancet, The, ISSN 0140-6736, 2016, Volume 388, Issue 10044, pp. 565 - 575
Journal Article
Lancet Oncology, The, ISSN 1470-2045, 2013, Volume 14, Issue 6, pp. 525 - 533
Journal Article
Lancet, The, ISSN 0140-6736, 2011, Volume 377, Issue 9759, pp. 42 - 51
Journal Article
Lancet, The, ISSN 0140-6736, 2011, Volume 378, Issue 9806, pp. 1858 - 1867
Summary Background The outcome of diffuse large B-cell lymphoma has been substantially improved by the addition of the anti-CD20 monoclonal antibody rituximab... 
Internal Medicine | MEDICINE, GENERAL & INTERNAL | MULTICENTER | RESPONSE CRITERIA | AGGRESSIVE LYMPHOMAS | POOR-PROGNOSIS | NON-HODGKINS-LYMPHOMA | REGIMEN | YOUNG-PATIENTS | ELDERLY-PATIENTS | DES-LYMPHOMES | TRANSPLANTATION | Cyclophosphamide - administration & dosage | Antineoplastic Combined Chemotherapy Protocols - administration & dosage | Prospective Studies | Follow-Up Studies | Humans | Middle Aged | Antibodies, Monoclonal, Murine-Derived - administration & dosage | Antineoplastic Combined Chemotherapy Protocols - adverse effects | Male | Cyclophosphamide - adverse effects | Dose-Response Relationship, Drug | Young Adult | Vindesine - adverse effects | Adult | Female | Prednisolone | Doxorubicin - administration & dosage | Severity of Illness Index | Prednisone - administration & dosage | Lymphoma, Large B-Cell, Diffuse - drug therapy | Prednisone - adverse effects | Drug Administration Schedule | Risk Assessment | Rituximab | Treatment Outcome | Bleomycin - administration & dosage | Bleomycin - adverse effects | Vincristine | Lymphoma, Large B-Cell, Diffuse - mortality | Disease-Free Survival | Lymphoma, Large B-Cell, Diffuse - diagnosis | Maximum Tolerated Dose | Adolescent | Survival Analysis | Vindesine - administration & dosage | Doxorubicin - adverse effects | Chemotherapy | Physiological aspects | Lymphomas | B cells | Drug therapy | Methods | Cancer | Dehydrogenases | Toxicity | Population studies | Doxorubicin | Hepatitis | Randomization | Bleomycin | Motivation | Drug dosages | Neutropenia | Cell survival | Hematology | Prednisone | Survival | Patients | Lymphoma | Cyclophosphamide | Lymphocytes B | Monoclonal antibodies | CD20 antigen | Tumors | B-cell lymphoma | Clinical trials | Public speaking | Grants | Clinical medicine | Side effects | lymphoma | survival | International standardization | chemotherapy
Journal Article
Lancet Oncology, The, ISSN 1470-2045, 2015, Volume 16, Issue 6, pp. 704 - 715
Journal Article
Lancet, The, ISSN 0140-6736, 2016, Volume 387, Issue 10036, pp. 2402 - 2411
Summary Background Short intensive chemotherapy is the standard of care for adult patients with Burkitt's leukaemia or lymphoma. Findings from single-arm... 
Internal Medicine | MEDICINE, GENERAL & INTERNAL | CODOX-M/IVAC | CLEAVED-CELL LYMPHOMA | ACUTE-LYMPHOBLASTIC-LEUKEMIA | MULTIAGENT CHEMOTHERAPY | ADOLESCENTS | PLUS RITUXIMAB | NON-HODGKIN-LYMPHOMA | SURVIVAL RATE | PEDIATRIC-ONCOLOGY-SOCIETY | CHILDREN | Cyclophosphamide - administration & dosage | Antineoplastic Combined Chemotherapy Protocols - administration & dosage | Injections, Intravenous | Humans | Middle Aged | Antineoplastic Combined Chemotherapy Protocols - adverse effects | Male | Patient Selection | Burkitt Lymphoma - pathology | Hydrocortisone - administration & dosage | Vincristine - administration & dosage | Adult | Female | France | Odds Ratio | Burkitt Lymphoma - drug therapy | Doxorubicin - administration & dosage | Prednisone - administration & dosage | Drug Administration Schedule | Biomarkers, Tumor - analysis | Proportional Hazards Models | Treatment Outcome | Burkitt Lymphoma - diagnosis | Burkitt Lymphoma - chemistry | Cytarabine - administration & dosage | Rituximab - administration & dosage | Antineoplastic Combined Chemotherapy Protocols - therapeutic use | Methotrexate - administration & dosage | Aged | Bone Marrow Neoplasms - drug therapy | Neoplasm Staging | Central Nervous System Neoplasms - drug therapy | Methylprednisolone - administration & dosage | Chemotherapy | Leukemia | Lymphomas | Adults | Epidemiology | Biometry | Cancer | Survival analysis | Biomedical research | Dehydrogenases | Medical prognosis | Clinical trials
Journal Article
The Lancet, ISSN 0140-6736, 02/2018, Volume 391, Issue 10121, pp. 659 - 667
Journal Article
European Journal of Haematology, ISSN 0902-4441, 02/2015, Volume 94, Issue 2, pp. 120 - 129
Journal Article